ClinicalTrials.Veeva

Menu

A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation

H

Hong Kong Baptist University

Status and phase

Completed
Phase 2

Conditions

Constipation

Treatments

Drug: MaZiRenWan (MZRW) High dose
Drug: MaZiRenWan (MZRW) Median dose
Drug: MaZiRenWan (MZRW) Low dose

Study type

Interventional

Funder types

Other

Identifiers

NCT00299975
PID-001

Details and patient eligibility

About

Functional constipation (FC) is common with 14.3% estimated prevalence in Hong Kong, but treatment for this condition in conventional medicine is suboptimal. Complementary and alternative medicines, especially Chinese herbal medicine (CHM) are used frequently by patients with FC, but there is little research evidence about these commonly used CHM. The purpose of the study is evaluate the efficacy and safety of CHM, as well as determining the optimal dosage.

Full description

Functional constipation (FC) is a common complaint in clinical practice, with the estimated prevalence 14.3% in Hong Kong, as nearly affecting 1 million Hong Kong People in different extent. It is comparable with western population, which is 15% in North America. By the definition of Rome II criteria, FC comprises a group of functional disorders, which presents as persistent difficult, infrequent or seemingly incomplete defecation.

Constipation is often perceived to be benign, easily treated condition with short-term treatment being relatively straightforward. However, the fact is the management of FC is perplexed as some subjects complain of constipation more than decade. Moreover, chronic constipation can develop into more serious bowel complaints, such as faecal impaction, incontinence and bowel perforations. There is also accumulating evidence shown that constipated subjects have significantly higher anxiety and depression scores and lower quality of life. Therefore, the demand of effective agents to normalize bowel function is extremely large.

Conventional treatment for constipation mainly relies on dietary fibre and laxatives. Although there is no credible evidence that any serious problem is associated with their prolonged use, the treatment of it has been suboptimal. First, a recent systematic review pointed out that there were paucity of trials for many commonly used agents, therefore, their use might not be well validated. Second, many patients with severe constipation do not respond adequately or lose of effectiveness after a short period of time. Third, many patients who intake dietary fibre complain of flatulence, distension, bloating and poor taste. As a result, the compliance is low as about 50%. Fourth, the use of osmotic laxatives, such as polyethylene glycol, become increasingly popular due to fewer side effects and better taste, however, the prices are much more expensive than other medications. Many constipation sufferers seek help from alternative medicine, especially from Chinese herbal medicine. For example, according to a telephone survey in Hong Kong, more than 85% of constipated subjects seek for coping strategies, such as asking for medical consultations, taking prescribed medicine and seeking for alternative therapy, involving Chinese medicine.

Traditional Chinese medicine (TCM) is particularly attractive as their effectiveness in treating functional disorders and retaining balance of body functions. The CHM used in study is derived from classic text of Chinese medicine (Shang Han Lun, Discussion of Cold-induced Disorders), which can "moisten the intestines, drain heat, promote the movement of qi and unblock the bowel".

It is well known that randomized controlled trial (RCT) is the gold standard to test the efficacy of intervention, thus in this project, we attempt to follow the basic requirements of RCT to testify the efficacy and safety of CHM on FC, as well as to determine the optimal dosage. We believe such study will benefit the advancement of CHM, or even as the foundation of research study in future.

Enrollment

97 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Clinical diagnosis of functional constipation with Rome II criteria
  • General stool type belongs to Type 1 to 4 according to Bristol Stool Form Scale
  • Complete spontaneous bowel movement≦2 movements per week

Exclusion criteria

  • Anti-diarrhoeal therapy
  • Drug-induced constipation
  • Medical history of important bowel pathology, such as inflammatory bowel disease, congenital or acquired megacolon / megarectum
  • Medical history of previous abdominal surgery
  • Taking chronic medications that contain any kind of herbs, mineral, or specific vitamin supplements
  • Medical history of carbohydrate malabsorption, hormonal disorder, cancer, diabetes mellitus, hypothyroidism, asthma, renal impairment and/or any other serious diseases
  • History of laxative abuse
  • History of allergy to Chinese herbal medicine
  • Psychiatric or addictive disorders
  • Pregnancy or breast-feeding
  • Any other serious diseases

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

97 participants in 3 patient groups

MaZiRenWan (MZRW) Low dose
Experimental group
Description:
MaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks
Treatment:
Drug: MaZiRenWan (MZRW) Low dose
MaZiRenWan (MZRW) Median dose
Experimental group
Description:
MaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks
Treatment:
Drug: MaZiRenWan (MZRW) Median dose
MaZiRenWan (MZRW) High dose
Experimental group
Description:
MaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks
Treatment:
Drug: MaZiRenWan (MZRW) High dose

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems